Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
65.26
-0.06 (-0.09%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Guardant Health Revenue
Guardant Health had revenue of $232.09M in the quarter ending June 30, 2025, with 30.95% growth. This brings the company's revenue in the last twelve months to $828.85M, up 28.74% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$828.85M
Revenue Growth
+28.74%
P/S Ratio
9.74
Revenue / Employee
$410,118
Employees
2,021
Market Cap
8.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GH News
- 14 hours ago - Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - Business Wire
- 10 days ago - FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer - Business Wire
- 15 days ago - Guardant Health, Inc. (GH) Analyst/Investor Day Transcript - Seeking Alpha
- 15 days ago - Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States - Business Wire
- 24 days ago - Alex M. Azar II Joins Guardant Health Board of Directors - Business Wire
- 4 weeks ago - Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership - Business Wire
- 4 weeks ago - Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States - Business Wire